About

Dr. Roger Sawhney has served as a director of Actuate Therapeutics since August 2024. He currently serves as Chief Business Officer of both Regor Pharmaceuticals and Neuvogen, and was previously Chief Financial Officer of LB Pharmaceuticals, Inc. (2024-2025) and of Garuda Therapeutics, Inc. (2022-2023). He earlier served as Chief Business Officer and then Chief Financial Officer of Omega Therapeutics, Inc., as Director of the healthcare investment platform at KKR & Co., as Senior Vice President and Head of Global Corporate Strategy at Novartis AG, and as a Partner at Bain & Company and Managing Director at the Boston Consulting Group. He serves as a director of Arbutus Biopharma and Adlai Nortye Ltd., among other companies. Dr. Sawhney earned an M.D. from Harvard Medical School and a B.A. in Economics from Stanford University.

Roles

Actuate Therapeutics, Inc.
Director · Current role
August 2024–present
Regor Pharmaceuticals / Neuvogen
Chief Business Officer
present
LB Pharmaceuticals, Inc.
Chief Financial Officer
2024 - 2025
Garuda Therapeutics, Inc.
Chief Financial Officer
2022 - 2023
Omega Therapeutics, Inc.
Chief Business Officer / Chief Financial Officer
2020 - 2022
KKR & Co.
Director, Healthcare Investment Platform
2018 - 2020
Novartis AG
SVP & Head of Global Corporate Strategy
2009 - 2012

External Roles

Arbutus Biopharma
Director
2025 - present
Adlai Nortye Ltd.
Director
2024 - present

Director Compensation

FY 2025
Fees earned or paid in cash
$55,500
ComponentAnnual cash retainers and committee/chair fees earned in 2025
Option awards
$103,995
ComponentAnnual stock option grant (15,000 shares, May 22, 2025), ASC 718 grant-date fair value
Total
$159,495

Also at Actuate Therapeutics, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.